Greater efficacy and fewer infusion reactions were seen with methotrexate-pegloticase combination than pegloticase alone in the placebo-controlled MIRROR trial.

Study identified factors and strategies for maintaining response

23% achieved HBsAg loss with xalnesiran plus immunomodulator, but relapses occurred in some

These data rule out the study hypothesis that a BTKi offers greater protection against relapse than a commonly used immunomodulator.

Lower healthcare costs and efficacy put rituximab ahead of traditional treatments, such as corticosteroids, doxycycline, and immunomodulators, for the autoimmune blistering disease, an expert said.

If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patientsSince the beginning...

The two experts based their arguments largely on the same two studies, the only randomized trials to tackle the issue to date.

In a new study launched to better understand headache as a side effect of medication use, the top five most frequently implicated meds were all treatments for autoimmune disorders.

Prior to this trial, intravenous immune globulin had not been fully studied for the treatment of dermatomyositis.

Patients with early ileocecal Crohn's disease who undergo ileocecal surgery remain off drug treatment 5 years later.

The scoring system could assist with accurate severity assessment and choice of medical treatment.

The phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma.

Including 24-hour urine testing in multiple myeloma response assessments is largely unnecessary, a new phase 3 trial suggests.

Researchers evaluated results of seven major studies to compare efficacy and safety of the two agents in Crohn's disease and ulcerative colitis.

With an abundance of targeted therapies transforming the treatment landscape for chronic lymphocytic leukemia, picking the optimal drug or regimen for the right situation can be a challenge.

Dupilumab monotherapy was associated with lower odds of hospitalizations compared with other therapies.

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal residual disease.

Mirikizumab targets a subunit of interleukin 23, which has shown promise in other conditions.

The likelihood of long-term accumulation of disability in patients with multiple sclerosis is significantly lower if the more potent drug is started first.

A fixed-dose combination of a LAG-3 and PD-1 inhibitor provides a meaningful progression-free survival benefit over PD-1 inhibition alone in previously untreated metastatic or inoperable melanoma.